Alopecia areata (AA) imposes a complex, multidimensional burden that extends far beyond visible hair loss, with psychosocial distress often shaped more by individual perceptions and stigma than disease severity. Treatment success should prioritise patient-reported outcomes, including psychological wellbeing and social functioning, rather than focusing solely on hair regrowth. While advances such as JAK inhibitors have improved clinical and quality-of-life outcomes, significant inequities in access to both medical and supportive therapies persist, limiting optimal care. Additionally, the substantial and often overlooked financial burden of AA underscores the need for more equitable healthcare policies and cost-effective treatment strategies.
Potluru et al. (Tue,) studied this question.